LitAlert ~~ GeneLit.com

    • Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    • Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S.
    • Br J Cancer. 2022 Jul 22. doi: 10.1038/s41416-022-01897-1. Epub ahead of print.

    Identifier: NCT02408536: Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22). (ClinicalTrials.gov)

    • Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance.
    • Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta MA, Cocciolillo F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 Jul 22:ijgc-2022-003543. doi: 10.1136/ijgc-2022-003543. Epub ahead of print.
    • CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    • You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM.
    • J Clin Oncol. 2022 Jul 22:JCO2200430. doi: 10.1200/JCO.22.00430. Epub ahead of print.
    • A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.
    • Torr B, Jones C, Choi S, Allen S, Kavanaugh G, Hamill M, Garrett A, MacMahon S, Loong L, Reay A, Yuan L, Valganon Petrizan M, Monson K, Perry N, Fallowfield L, Jenkins V, Gold R, Taylor A, Gabe R, Wiggins J, Lucassen A, Manchanda R, Gandhi A, George A, Hubank M, Kemp Z, Evans DG, Bremner S, Turnbull C.
    • J Med Genet. 2022 Jul 22:jmedgenet-2022-108655. doi: 10.1136/jmg-2022-108655. Epub ahead of print.

    Trial registration number: ISRCTN87845055: BRCA-DIRECT- Is digitally delivered information about genetic testing feasible, effective and acceptable to women with breast cancer?. (ISRCTN registry)

    • Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
    • Ossa Gomez CA, Achatz MI, Hurtado M, Sanabria-Salas MC, Sullcahuaman Y, Chávarri-Guerra Y, Dutil J, Nielsen SM, Esplin ED, Michalski ST, Bristow SL, Hatchell KE, Nussbaum RL, Pineda-Alvarez DE, Ashton-Prolla P.
    • JCO Glob Oncol. 2022 Jul;8:e2200104. doi: 10.1200/GO.22.00104.